Literature DB >> 30981686

A global scientific strategy to cure hepatitis B.

Peter A Revill1, Francis V Chisari2, Joan M Block3, Maura Dandri4, Adam J Gehring5, Haitao Guo6, Jianming Hu7, Anna Kramvis8, Pietro Lampertico9, Harry L A Janssen10, Massimo Levrero11, Wenhui Li12, T Jake Liang13, Seng-Gee Lim14, Fengmin Lu15, M Capucine Penicaud16, John E Tavis17, Robert Thimme18, Fabien Zoulim19.   

Abstract

Chronic hepatitis B virus (HBV) infection is a global public health challenge on the same scale as tuberculosis, HIV, and malaria. The International Coalition to Eliminate HBV (ICE-HBV) is a coalition of experts dedicated to accelerating the discovery of a cure for chronic hepatitis B. Following extensive consultation with more than 50 scientists from across the globe, as well as key stakeholders including people affected by HBV, we have identified gaps in our current knowledge and new strategies and tools that are required to achieve HBV cure. We believe that research must focus on the discovery of interventional strategies that will permanently reduce the number of productively infected cells or permanently silence the covalently closed circular DNA in those cells, and that will stimulate HBV-specific host immune responses which mimic spontaneous resolution of HBV infection. There is also a pressing need for the establishment of repositories of standardised HBV reagents and protocols that can be accessed by all HBV researchers throughout the world. The HBV cure research agenda outlined in this position paper will contribute markedly to the goal of eliminating HBV infection worldwide.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30981686      PMCID: PMC6732795          DOI: 10.1016/S2468-1253(19)30119-0

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


  122 in total

1.  Viral clearance without destruction of infected cells during acute HBV infection.

Authors:  L G Guidotti; R Rochford; J Chung; M Shapiro; R Purcell; F V Chisari
Journal:  Science       Date:  1999-04-30       Impact factor: 47.728

2.  A "NEW" ANTIGEN IN LEUKEMIA SERA.

Authors:  B S BLUMBERG; H J ALTER; S VISNICH
Journal:  JAMA       Date:  1965-02-15       Impact factor: 56.272

3.  Proteolytic processing of the hepatitis B virus e antigen precursor. Cleavage at two furin consensus sequences.

Authors:  Fabienne Messageot; Samia Salhi; Patricia Eon; Jean-Michel Rossignol
Journal:  J Biol Chem       Date:  2002-11-01       Impact factor: 5.157

4.  Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection.

Authors:  Simona Urbani; Carolina Boni; Barbara Amadei; Paola Fisicaro; Simona Cerioni; Maria Antonietta Valli; Gabriele Missale; Carlo Ferrari
Journal:  Hepatology       Date:  2005-04       Impact factor: 17.425

5.  Structural organization of the hepatitis B virus minichromosome.

Authors:  C T Bock; S Schwinn; S Locarnini; J Fyfe; M P Manns; C Trautwein; H Zentgraf
Journal:  J Mol Biol       Date:  2001-03-16       Impact factor: 5.469

6.  CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection.

Authors:  Robert Thimme; Stefan Wieland; Carola Steiger; John Ghrayeb; Keith A Reimann; Robert H Purcell; Francis V Chisari
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

7.  Toll-like receptor signaling inhibits hepatitis B virus replication in vivo.

Authors:  Masanori Isogawa; Michael D Robek; Yoshihiro Furuichi; Francis V Chisari
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 8.  Immune responses in hepatitis B virus infection.

Authors:  Barbara Rehermann
Journal:  Semin Liver Dis       Date:  2003-02       Impact factor: 6.115

9.  Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus.

Authors:  Dieter Glebe; Mehriar Aliakbari; Peter Krass; Eva V Knoop; Klaus P Valerius; Wolfram H Gerlich
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

Authors:  Bettina Werle-Lapostolle; Scott Bowden; Stephen Locarnini; Karsten Wursthorn; Jorg Petersen; George Lau; Christian Trepo; Patrick Marcellin; Zachary Goodman; William E Delaney; Shelly Xiong; Carol L Brosgart; Shan-Shan Chen; Craig S Gibbs; Fabien Zoulim
Journal:  Gastroenterology       Date:  2004-06       Impact factor: 22.682

View more
  122 in total

1.  Conservation of the HBV RNA element epsilon in nackednaviruses reveals ancient origin of protein-primed reverse transcription.

Authors:  Jürgen Beck; Stefan Seitz; Chris Lauber; Michael Nassal
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-30       Impact factor: 11.205

2.  An Alternatively Spliced Sirtuin 2 Isoform 5 Inhibits Hepatitis B Virus Replication from cccDNA by Repressing Epigenetic Modifications Made by Histone Lysine Methyltransferases.

Authors:  Zahra Zahid Piracha; Umar Saeed; Jumi Kim; Hyeonjoong Kwon; Yong-Joon Chwae; Hyun Woong Lee; Jin Hong Lim; Sun Park; Ho-Joon Shin; Kyongmin Kim
Journal:  J Virol       Date:  2020-07-30       Impact factor: 5.103

Review 3.  Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential.

Authors:  Yuchen Xia; Haitao Guo
Journal:  Antiviral Res       Date:  2020-05-22       Impact factor: 5.970

Review 4.  HBV replication inhibitors.

Authors:  Claire Pierra Rouviere; Cyril B Dousson; John E Tavis
Journal:  Antiviral Res       Date:  2020-05-05       Impact factor: 5.970

Review 5.  Revisiting Hepatitis B Virus: Challenges of Curative Therapies.

Authors:  Jianming Hu; Ulrike Protzer; Aleem Siddiqui
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

Review 6.  The evolution and clinical impact of hepatitis B virus genome diversity.

Authors:  Peter A Revill; Thomas Tu; Hans J Netter; Lilly K W Yuen; Stephen A Locarnini; Margaret Littlejohn
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-05-28       Impact factor: 46.802

7.  Quantification, epitope mapping and genotype cross-reactivity of hepatitis B preS-specific antibodies in subjects vaccinated with different dosage regimens of BM32.

Authors:  Inna Tulaeva; Carolin Cornelius; Petra Zieglmayer; René Zieglmayer; René Schmutz; Patrick Lemell; Milena Weber; Margarete Focke-Tejkl; Alexander Karaulov; Rainer Henning; Rudolf Valenta
Journal:  EBioMedicine       Date:  2020-08-24       Impact factor: 8.143

8.  Characterization of the Termini of Cytoplasmic Hepatitis B Virus Deproteinated Relaxed Circular DNA.

Authors:  Dawei Cai; Ran Yan; Jerry Z Xu; Hu Zhang; Sheng Shen; Bidisha Mitra; Alexander Marchetti; Elena S Kim; Haitao Guo
Journal:  J Virol       Date:  2020-12-09       Impact factor: 5.103

9.  The Dihydroquinolizinone Compound RG7834 Inhibits the Polyadenylase Function of PAPD5 and PAPD7 and Accelerates the Degradation of Matured Hepatitis B Virus Surface Protein mRNA.

Authors:  Liren Sun; Fang Zhang; Fang Guo; Fei Liu; Jessie Kulsuptrakul; Andreas Puschnik; Min Gao; Rene Rijnbrand; Michael Sofia; Timothy Block; Tianlun Zhou
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

10.  Amide-containing α-hydroxytropolones as inhibitors of hepatitis B virus replication.

Authors:  Qilan Li; Elena Lomonosova; Maureen J Donlin; Feng Cao; Austin O'Dea; Brienna Milleson; Alex J Berkowitz; John-Charles Baucom; John P Stasiak; Daniel V Schiavone; Rudolf G Abdelmessih; Anastasiya Lyubimova; Americo J Fraboni; Lauren P Bejcek; Juan A Villa; Emilio Gallicchio; Ryan P Murelli; John E Tavis
Journal:  Antiviral Res       Date:  2020-03-23       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.